A new report challenges assertions made during the committee’s recent hearing on the role of pharmacy benefit managers.
The FTC Wrongly Blames PBMs for High Drug Prices
The FTC fails to acknowledge the benefits of pharmacy benefit managers and wrong blames them for high drug prices.
Another Government Report Proves That PBMs Save Taxpayers Money
PBMs lower healthcare costs and another government agency overspent because a PBM was not used.
Attacking PBMs Won’t Result in Lower Drug Costs
SB 1550 will negatively impact Florida’s private sector healthcare market and ultimately harm patients.
The Cantwell-Grassley PBM Bill is a Wolf in Sheep’s Clothing
A Bill introduced in the Senate takes aim at PBMS and private sector healthcare.
House Committees Hold Oversight Hearings on COVID-19 Relief Fraud
Long overdue oversight hearings were finally held in the House of Representatives.
CCAGW Year in Review in the States
In 2022, CCAGW helped protect taxpayers with wins on data privacy, broadband spending, drug price controls, and reducing red tape.
Regulating PBMs Will Not Lower Drug Costs
Increasing regulations on pharmacy benefit managers will not reduce the cost of pharmaceuticals.
President Biden Again Tries to Undermine U.S. Biomedical Innovation
President Biden’s support of intellectual property waivers threatens development of future life-saving medicines.
Connecticut to Increase CON law Fees by 4,900 Percent
Connecticut should avoid higher fees for CON laws that increase costs and limit access to quality healthcare.